Evidence map›Paper›PMID 26143582›Full record

ReviewExperimental hematology2015

An international effort to cure a global health problem: A report on the 19th Hemoglobin Switching Conference.

Gerd A Blobel, David Bodine, Marjorie Brand, John Crispino, Marella F T R de Bruijn, David Nathan, Thalia Papayannopoulou, Catherine Porcher, John Strouboulis, Len Zon and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Evolving treatment paradigms in sickle cell disease.Hematology. American Society of Hematology. Education Program · 2017
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gerd A BlobelDivision of Hematology, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
David BodineNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Marjorie BrandSprott Center for Stem Cell Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
John CrispinoDivision of Hematology/Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Marella F T R de BruijnMRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital University of Oxford, Oxford, UK; BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford University Hospital, Oxford, UK.
David NathanDivision of Hematology and Oncology, Boston Children's Hospital, Departments of Pediatrics and Medicine, Harvard Medical School, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Thalia PapayannopoulouDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Catherine PorcherMRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital University of Oxford, Oxford, UK; BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford University Hospital, Oxford, UK.
John StrouboulisDivision of Molecular Oncology, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.
Len ZonBoston Children's Hospital/HHMI, Boston, MA, USA.
Douglas R HiggsMRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital University of Oxford, Oxford, UK; BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford University Hospital, Oxford, UK.
George StamatoyannopoulosDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
James Douglas EngelDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address: engel@umich.edu.

Funding

Hematopoietic Stem Cell BiologyZIAHG000083 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BODINE, DAVID M. · 2009 to 2022
$12.1M
Red Cell BiologyZIAHG200339 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BODINE, DAVID M. · 2009 to 2022
$11.8M
Improving HbF induction by inhibiting epigenetic target enzymesU01HL117658 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ENGEL, JAMES DOUGLAS, LAVELLE, DONALD · 2013 to 2017
$8.3M
EMBRYONIC HEMATOPOIESISR01HL048801 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 1992 to 2016
$5.7M
Medical Research Council G1000801Medical Research Council MC_U137961144Medical Research Council MC_U137961145Medical Research Council MC_UU_12009/2Medical Research Council MC_UU_12009/9NHLBI NIH HHS R01 HL048801NHLBI NIH HHS U01 HL117658
6 · The paper itself

Abstract

Every 2 years since 1978, an international group of scientists, physicians, and other researchers meet to discuss the latest developments in the underlying etiology, mechanisms of action, and developmental acquisition of cellular and systemic defects exhibited and elicited by the most common inherited human disorders, the hemoglobinopathies. The 19th Hemoglobin Switching Conference, held in September 2014 at St. John's College in Oxford, once again exceeded all expectations by describing cutting edge research in cellular, molecular, developmental, and genomic advances focused on these diseases. The conference comprised about 60 short talks over 3 days by leading investigators in the field. This meeting report describes the highlights of the conference.

Indexed as

Congresses as TopicHemoglobinopathiesHemoglobinsHumansHemoglobins

Identifiers

PMID26143582
PMCPMC5490074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.